Tobira Therapeutics Announces Data Presentations Highlighting Cenicriviroc at HEP DART 2015
December 8, 2015Tobira and key collaborators presented two abstracts and a sponsor presentation on CVC, the company's lead CCR2/5 antagonist; CENTAUR, the company's Phase 2b study evaluating CVC in NASH; and ELF index data from the company's completed HIV Phase 2b study.
More »
Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial
December 8, 2015AF-130 is the second candidate from Afferent’s P2X3 development pipeline to enter the clinic.
More »
Neothetics Announces Issuance by USPTO of Fourth Patent Directed to LIPO-202 Lead Clinical Asset
December 7, 2015This patent is directed to specific methods of using LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
More »